Co-Diagnostics Statistics

Total Valuation

Co-Diagnostics has a market cap or net worth of $5.87 million. The enterprise value is -$4.92 million.

Market Cap	5.87M
Enterprise Value	-4.92M

Important Dates

The next estimated earnings date is Thursday, May 14, 2026, after market close.

Earnings Date	May 14, 2026
Ex-Dividend Date	n/a

Share Statistics

Co-Diagnostics has 3.60 million shares outstanding. The number of shares has increased by 31.55% in one year.

Current Share Class	3.60M
Shares Outstanding	3.60M
Shares Change (YoY)	+31.55%
Shares Change (QoQ)	+49.14%
Owned by Insiders (%)	2.86%
Owned by Institutions (%)	6.90%
Float	3.50M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	9.20
Forward PS	8.30
PB Ratio	0.17
P/TBV Ratio	0.43
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 3.87, with a Debt / Equity ratio of 0.06.

Current Ratio	3.87
Quick Ratio	3.42
Debt / Equity	0.06
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -125.89% and return on invested capital (ROIC) is -157.06%.

Return on Equity (ROE)	-125.89%
Return on Assets (ROA)	-44.28%
Return on Invested Capital (ROIC)	-157.06%
Return on Capital Employed (ROCE)	-147.54%
Weighted Average Cost of Capital (WACC)	9.95%
Revenue Per Employee	$5,413
Profits Per Employee	-$407,791
Employee Count	115
Asset Turnover	0.01
Inventory Turnover	0.22

Taxes

Income Tax	-1.62M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -84.48% in the last 52 weeks. The beta is 1.43, so Co-Diagnostics's price volatility has been higher than the market average.

Beta (5Y)	1.43
52-Week Price Change	-84.48%
50-Day Moving Average	2.07
200-Day Moving Average	7.16
Relative Strength Index (RSI)	44.43
Average Volume (20 Days)	137,088

Short Selling Information

The latest short interest is 45,702, so 1.27% of the outstanding shares have been sold short.

Short Interest	45,702
Short Previous Month	168,619
Short % of Shares Out	1.27%
Short % of Float	1.31%
Short Ratio (days to cover)	0.02

Income Statement

In the last 12 months, Co-Diagnostics had revenue of $622,489 and -$46.90 million in losses. Loss per share was -$35.25.

Revenue	622,489
Gross Profit	400,112
Operating Income	-31.28M
Pretax Income	-48.51M
Net Income	-46.90M
EBITDA	-30.18M
EBIT	-31.28M
Loss Per Share	-$35.25

Full Income Statement

Balance Sheet

The company has $11.88 million in cash and $1.24 million in debt, giving a net cash position of $10.65 million or $2.96 per share.

Cash & Cash Equivalents	11.88M
Total Debt	1.24M
Net Cash	10.65M
Net Cash Per Share	$2.96
Equity (Book Value)	20.63M
Book Value Per Share	9.85
Working Capital	10.15M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$29.14 million and capital expenditures -$700,047, giving a free cash flow of -$29.84 million.

Operating Cash Flow	-29.14M
Capital Expenditures	-700,047
Depreciation & Amortization	1.11M
Net Borrowing	n/a
Free Cash Flow	-29.84M
FCF Per Share	-$8.28

Full Cash Flow Statement

Margins

Gross Margin	64.28%
Operating Margin	-5,025.53%
Pretax Margin	-7,793.22%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Co-Diagnostics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-31.55%
Shareholder Yield	-31.55%
Earnings Yield	-818.73%
FCF Yield	-520.90%

Analyst Forecast

The average price target for Co-Diagnostics is $90.00, which is 5,421.47% higher than the current price. The consensus rating is "Buy".

Price Target	$90.00
Price Target Difference	5,421.47%
Analyst Consensus	Buy
Analyst Count	3
Revenue Growth Forecast (5Y)	120.48%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

The last stock split was on January 2, 2026. It was a reverse split with a ratio of 1:30.

Last Split Date	Jan 2, 2026
Split Type	Reverse
Split Ratio	1:30

Scores

Co-Diagnostics has an Altman Z-Score of -5.9 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-5.9
Piotroski F-Score	1